Hutchmed
Clinical trials sponsored by Hutchmed, explained in plain language.
Biopharmaceutical company developing cancer and immunology therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase: PHASE2, PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising ITP drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Will breakfast or heartburn pills change how this new drug works?
Knowledge-focused OngoingThis early-stage study will enroll 24 healthy adults to find out if food or the stomach-acid-reducing drug rabeprazole changes how the body absorbs an experimental drug called HMPL-760. Participants will take HMPL-760 under different conditions (fasting, with a high-fat meal, wit…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC